Lead Product(s): NT-814
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: NT-814
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Bayer AG
Deal Size: $875.0 million Upfront Cash: $425.0 million
Deal Type: Acquisition August 11, 2020
KaNDy Therapeutics Ltd. recently completed the Phase IIb with NT-814, a first in class, non-hormonal, once-daily, oral neurokinin-1,3 receptor antagonist, publishing positive data for the treatment of frequent symptoms of the menopause, hot flashes and night sweats.